In a recent legal development, Sandoz, the generic-drug manufacturing division of Novartis, faced a setback in a patent infringement lawsuit related to an eyelash growth drug. The company’s request for a new trial was denied by a Colorado federal judge. The decision comes after a jury awarded $39 million in damages to Allergan, the plaintiff.
The lawsuit revolved around the infringement of a patent by Sandoz for a medication designed to stimulate eyelash growth. After an intensive legal battle, the jury favored Allergan, resulting in a substantial financial outcome.
Sandoz petitioned for a new trial, challenging the verdict on the grounds that the court had errored in applying Federal Circuit precedent. The presiding judge, however, rejected this argument, thereby upholding the original verdict.
For further details on this legal development, you can read more here.